A Phase 1/2 interventional study of Ziftomenib and Midazolam in Advanced Malignant Neoplasm, Acute Myeloid Leukemia and Mixed Lineage Leukemia, sponsored by Kura Oncology, Inc.. Active, not recruiting at 43 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Kura Oncology, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing ziftomenib in Leukemia, Myeloid, Acute — 9 open to participants now, 11 under way, 1 of them phase 3. ziftomenib · Leukemia, Myeloid, Acute.
Among the 11 studies testing ziftomenib in Leukemia, Myeloid, Acute, this one is the 2nd largest by planned enrollment, is the only one that started in 2019, is the only one in phase 1/2, reaches primary completion later than 7 of the 10 other live ones, and was the 1st registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →9 of the 11 studies testing ziftomenib in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
Uma Borate · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 12+
Kyowa Kirin Co., Ltd. · Sites in Japan
Ages 18+
Kura Oncology, Inc. · Sites in United States, Australia, Belgium and 14 more countries
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
ziftomenib: first FDA approval 2025 (KOMZIFTI). What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 1
First in 2019; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 263 is above the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 44 across the 11 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
5 of 11 have an industry lead sponsor. The 5 most frequent:
Kura Oncology, Inc. is the lead sponsor of 18 studies on the registry; 8 are open to participants now.
Kura Oncology, Inc. has 6 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
5 of the studies testing ziftomenib in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06001788Kura Oncology, Inc.Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | 2026-12 |
| NCT07411586M.D. Anderson Cancer CenterPhase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia | 2027-01-14 |
| NCT07623616Kyowa Kirin Co., Ltd.A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia | 2027-03 |
| NCT06440135Massachusetts General HospitalZiftomenib Maintenance Post Allo-HCT | 2027-04-01 |
| NCT07355335Massachusetts General HospitalZiftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML | 2027-07-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 11 studies testing ziftomenib in Leukemia, Myeloid, Acute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies. In the Main Study (including Phase 1a, Phase 1b, and Phase 2 portions), ziftomenib will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment.
In Sub-studies 1 and 2, the effects of taking ziftomenib and other common drugs at the same time will be investigated in AML patients. In Sub-study 3, ziftomenib will be evaluated in patients with R/R acute lymphoblastic leukemia (ALL). In Sub-study 4, ziftomenib will be evaluated in patients with R/R AML with certain genetic mutations.
This first-in-human (FIH), open-label study will assess ziftomenib, a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The trial includes a Main Study and four sub-studies.
The Main Study is a Phase 1/2 dose-escalation and dose-validation/expansion study to assess ziftomenib in patients with R/R AML. The dose-escalation part of the study (Phase 1a) will determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D). The dose-validation/expansion part of the study (Phase 1b) will determine the safety, tolerability, and minimal biologically effective dose (MBED) of ziftomenib in biomarker-specific dosing cohorts from among doses that demonstrated early biological activity and are determined to be safe in the dose-escalation phase. The Phase 2 portion of the study will determine the safety, tolerability, and anti-leukemia activity of ziftomenib in patients with nucleophosmin 1-mutant (NPM1-m) AML.
In Sub-study 1, the effects of co-administration of ziftomenib on the pharmacokinetics (PK) of midazolam will be studied in patients with R/R AML with certain genetic mutations.
In Sub-study 2, the effects of co-administration of itraconazole on the PK of ziftomenib will be studied in patients with R/R AML with certain genetic mutations.
In Sub-study 3, the safety, tolerability, and MBED/RP2D of ziftomenib will be studied in patients with R/R KMT2A-rearranged (KMT2A-r) ALL (Phase 1a dose escalation). These parameters will be investigated further for the RP2D in a Phase 1b dose-validation/cohort expansion part of the sub-study.
In Sub-study 4, the clinical activity of ziftomenib will be studied in patients with R/R AML with certain genetic mutations.
Key Inclusion Criteria:
Patients with or relapsed AML defined as the reappearance of ≥ 5% blasts in the bone marrow and who have also failed or are ineligible for any approved standard of care therapies, including .
Phase 1b:
Phase 2:
Sub-studies:
Key Exclusion Criteria:
Treatment with concomitant drugs that are strong inhibitors or inducers of cytochrome P450-isozyme 3A4 (), as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AML patients will receive multiple doses of ziftomenib
Drug: Ziftomenib
Cohort 1: KMT2A-r / NPM1-m R/R AML patients will receive ziftomenib Cohort 2: KMT2A-r / NPM1-m R/R AML patients will receive ziftomenib
Drug: Ziftomenib
NPM1-m R/R AML patients will receive the recommended phase 2 ziftomenib dose
Drug: Ziftomenib
R/R AML patients with mutations associated with MEIS1 overexpression will receive ziftomenib + midazolam
Drug: Ziftomenib · Drug: Midazolam
R/R AML patients with mutations associated with MEIS1 overexpression will receive ziftomenib + itraconazole
Drug: Ziftomenib · Drug: Itraconazole
Part 1a: KMT2A-r R/R ALL patients will receive multiple ziftomenib doses Part 1b: KMT2A-r R/R ALL patients will receive ziftomenib
Drug: Ziftomenib
R/R AML patients with mutations associated with MEIS1 overexpression will receive ziftomenib
Drug: Ziftomenib
Oral administration
Also known as: KO-539
Oral administration
Also known as: Seizalam, Hypnovel, Dormicum
Oral administration
Also known as: Sporanox, Onmel, Tolsura
Phase 1a: Maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D)
MTD is defined as the highest dose that is not expected to cause dose limiting toxicity (DLT) in more than 20% of patients.
Time frame: Dose Limiting Toxicities (DLTs) will be evaluated during the first 28 days (1 cycle)
Phase 1b: Number of patients who experience Adverse Events (AEs) and Serious Adverse Events (SAEs)
Assessed by NCI-CTCAE v5.0
Time frame: During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first.
Phase 1b: Minimum biologically effective dose
Minimum biologically effective dose in dosing cohorts which have demonstrated biological activity and have been determined to be safe as a part of Part 1a
Time frame: For at least 12 months following end of treatment
Phase 1a, 1b, and 2: Evidence of anti-leukemia activity
Assessed by the CR + CRh rate
Time frame: For at least 12 months following end of treatment
Sub-study 1: Time to observed maximum plasma concentration (Tmax) of ziftomenib and midazolam
Tmax of ziftomenib, its metabolites, midazolam, and 1-hydroxymidazolam
Time frame: Cycle 1 on Days 1 and 15 at predose and postdose
Sub-study 1: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib and midazolam
AUC0-t of ziftomenib, its metabolites, midazolam, and 1-hydroxymidazolam
Time frame: Cycle 1 on Days 1 and 15 at predose and postdose
Sub-study 1: Maximum observed plasma concentration (Cmax) of ziftomenib and midazolam
Cmax of ziftomenib, its metabolites, midazolam, and 1-hydroxymidazolam
Time frame: Cycle 1 on Days 1 and 15 at predose and postdose
Sub-study 2: Time to observed maximum plasma concentration (Tmax) of ziftomenib and itraconazole
Tmax of ziftomenib, its metabolites, and itraconazole
Time frame: Cycle 1 on Days 1, 15, and 22 at predose and postdose
Sub-study 2: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib and itraconazole
AUC0-t of ziftomenib, its metabolites, and itraconazole
Time frame: Cycle 1 on Days 1, 15, and 22 at predose and postdose
Sub-study 2: Maximum observed plasma concentration (Cmax) of ziftomenib and itraconazole
Cmax of ziftomenib, its metabolites, and itraconazole
Time frame: Cycle 1 on Days 1, 15, and 22 at predose and postdose
Sub-study 3: Minimum biologically effective dose (MBED) and/or the recommended Phase 2 dose (RP2D)
Assessed by the number of patients that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) per NCI-CTCAE v5.0
Time frame: During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first
Sub-study 3: Minimum biologically effective dose (MBED) and/or the recommended Phase 2 dose (RP2D)
Assessed by CR
Time frame: For at least 12 months following end of treatment
Sub-study 3: Change in Eastern Cooperative Oncology Group (ECOG) status
To assess the change in ECOG status
Time frame: Timeframe: from Baseline to End of Treatment
Sub-study 3: Time to observed maximum plasma concentration (Tmax) of ziftomenib
Tmax of ziftomenib
Time frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards
Sub-study 3: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib
AUC0-t of ziftomenib
Time frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards
Sub-study 3: Maximum observed plasma concentration (Cmax) of ziftomenib
Cmax of ziftomenib
Time frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards.
Sub-study 4: Complete remission (CR) and complete remission with partial hematologic recovery (CRh)
To assess the CR+CRh rate
Time frame: For at least 12 months following end of treatment
Phase 1a and 2: Number of patients that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)
Assessed by NCI-CTCAE v5.0
Time frame: During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first.
Phase 1a: Tmax
Time to observed maximum plasma concentration of ziftomenib and/or its metabolites
Time frame: Cycle 1 and Cycle 2. Each cycle is 28 days.
Phase 1a: AUC(0-t)
Area under the plasma concentration-time curve from time 0 to time t of ziftomenib and/or its metabolites
Time frame: Cycle 1 and Cycle 2. Each cycle is 28 days.
Phase 1a: Cmax
Maximum plasma concentration of ziftomenib and/or its metabolites
Time frame: Cycle 1 and Cycle 2. Each cycle is 28 days.
Phases 1a, 1b, and 2: Complete remission (CR) and complete remission with partial hematologic recovery (CRh) measurable residual disease (MRD) negativity
To assess the CR/CRh MRD negativity
Time frame: For at least 12 months following discontinuation of treatment
Phases 1a, 1b, and 2: Duration of response (DOR)
To assess the DOR, defined as the duration of CR/CRh
Time frame: For at least 12 months following discontinuation of treatment
Phases 1a, 1b, and 2: Transfusion independence (TI)
To assess transfusion independence
Time frame: For at least 12 months following discontinuation of treatment
Phases 1a, 1b, and 2: Overall response rate (ORR)
To assess the ORR
Time frame: For at least 12 months following discontinuation of treatment
Phases 1a, 1b, and 2: Event-free survival (EFS)
To assess event-free survival
Time frame: For at least 12 months following end of treatment
Phases 1a, 1b, and 2: Overall survival (OS)
To assess overall survival
Time frame: For at least 12 months following end of treatment
Phases 1a, 1b, and 2: Composite complete remission (CRc)
To assess CRc
Time frame: For at least 12 months following discontinuation of treatment
Phases 1b and 2: Composite complete remission (CRc) measurable residual disease (MRD) negativity
To assess the CRc MRD negativity
Time frame: For at least 12 months following discontinuation of treatment
Phases 1b and 2: Overall response rate (ORR) measurable residual disease (MRD) negativity
To assess the ORR MRD negativity
Time frame: For at least 12 months following discontinuation of treatment
Sub-study 2: Corrected QT (QTc) intervals
Assessed by QTc intervals
Time frame: During Cycle 1
Sub-study 3: Complete remission (CR) measurable residual disease (MRD) negativity
To assess the CR MRD negativity
Time frame: For at least 12 months following discontinuation of treatment
Sub-studies 3 and 4: Composite complete remission (CRc)
To assess CRc
Time frame: For at least 12 months following discontinuation of treatment
Sub-study 3: Duration of response (DOR)
To assess the DOR, defined as the duration of CR
Time frame: For at least 12 months following discontinuation of treatment
Sub-studies 3 and 4: Overall survival (OS)
To assess overall survival
Time frame: For at least 12 months following discontinuation of treatment
Sub-studies 3 and 4: Event-free survival (EFS)
To assess event-free survival
Time frame: For at least 12 months following discontinuation of treatment
Sub-study 4: Transfusion independence (TI)
To assess transfusion independence
Time frame: For at least 12 months following discontinuation of treatment
Sub-studies 3 and 4: Overall response rate (ORR) measurable residual disease (MRD) negativity
To assess the ORR MRD negativity
Time frame: For at least 12 months following discontinuation of treatment
Sub-study 4: Number of patients that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)
Assessed by NCI-CTCAE v5.0
Time frame: During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first.
Sub-study 4: Duration of response (DOR)
To assess the DOR, defined as the duration of CR/CRh
Time frame: For at least 12 months following discontinuation of treatment
Sub-study 4: Time to observed maximum plasma concentration (Tmax) of ziftomenib
Tmax of ziftomenib and its metabolites
Time frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose on Cycle 2 onwards
Sub-study 4: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib
AUC0-t of ziftomenib and its metabolites
Time frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose on Cycle 2 onwards
Sub-study 4: Maximum plasma concentration (Cmax) of ziftomenib
Cmax of ziftomenib and its metabolites
Time frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose on Cycle 2 onwards
Plan to share: Undecided
Started Sep 2019 (actual). Primary completion is estimated for Oct 2028, 109 months after the start.
Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's planned 109 months is above that.
Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ziftomenib
Kura Oncology, Inc.